In the study of Darakhshan and Ghanbari [35] administration of tranilast with tamoxifen (TAM) downregulated the expression of TGF-β1, β-2, and β-3, as well as TβRI and TβRII in breast cancer cells (MCF-7 and MDA-MB-231 human breast cancer cell lines). This evidence concerns the gene TGFBR2 and breast carcinoma.